Recent data from the FELIX trial evaluating obecabtagene autoleucel in patients with relapsed and/or refractory B acute lymphoblastic leukaemia (R/R B-ALL) suggest that this novel intermediate-affinity CD19-directed chimeric antigen receptor (CAR) T cell therapy is associated with a reduced incidence of severe immune-mediated toxicities compared with other commercially available CAR T cell products. The increasing… Continue reading Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL
Tag: Vaccines and Immunization
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Background Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. When used in real-world settings, tisagenlecleucel has shown similar efficacy and improved safety compared with previous clinical trials. However, long-term data on… Continue reading Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
TWiV 1191: The pandemic duo
TWiV reviews freezes and unfreezes of US government grants, how prior COVID-19 vaccination prevents over-reaction of the innate immune response during infections, and how bat genomes illuminate adaptations to viral tolerance and disease resistance. Hosts: Vincent Racaniello and Alan Dove Click arrow to playDownload TWiV 1191 (63 MB .mp3, 105 min) Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV!… Continue reading TWiV 1191: The pandemic duo
TWiV 1190: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss changes in access to public health information and aid mechanisms such as the return of MMWR, the largest tuberculosis outbreak in the US ever, lack of USAID in fighting Marburg and Ebola outbreaks in Africa, discussing if avian influenza virus is airborne, how eggs… Continue reading TWiV 1190: Clinical update with Dr. Daniel Griffin
Standardization, validation, and comparative evaluation of a convenient surrogate recombinant vesicular stomatitis virus plaque reduction test for quantification of Hantaan orthohantavirus (HTNV) neutralizing antibodies
Hantaan orthohantavirus (HTNV) is responsible for severe hemorrhagic fever with renal syndrome (HFRS), which has a case fatality rate of 1% to 10%. Currently, the inactive vaccine licensed in endemic areas eli… Continue reading on BioMed Central
Afraid of needles? Try lotion: Engineering skin commensals for vaccination
Science Immunology, Volume 10, Issue 104, February 2025.
Evaluation of humoral immune response and milk antibody transfer in calves and lactating cows vaccinated with inactivated H5 avian influenza vaccine
Abstract The detection of Highly Pathogenic Avian Influenza (HPAI) A(H5N1) in dairy cattle in the United States has raised concerns about human exposure. This study evaluated the efficacy of various doses of an inactivated H5 AI vaccine in cattle and assessed antibody transfer in milk against a recent bovine isolate of HPAI A(H5N1, clade 2.3.4.4b).… Continue reading Evaluation of humoral immune response and milk antibody transfer in calves and lactating cows vaccinated with inactivated H5 avian influenza vaccine
Real-life observation of wildfire-smoke impaired COVID-19 vaccine immunity
An Extremely Successful Vaccine Story
by Gertrud U. Rey One of the most noteworthy advances in biomedical science is the vaccine for human papillomavirus (HPV). It has significantly changed the diagnostic and prognostic landscape in the field of cervical cancer. Cervical cancer is the fourth most common cancer in women globally, and it is a particular problem in low-income countries… Continue reading An Extremely Successful Vaccine Story
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens
Background Enhancing antigen cross-presentation is essential for the development of a tumor neoantigen vaccine. One approach is to stimulate antigen-presenting cells (APCs) to uptake neoantigens. Mycobacterium tuberculosis (MTb) contains pathogen-associated molecular patterns (PAMPs) recognized by APCs and adhesion molecules that facilitate MTb invasion of APCs. Therefore, we suggest using MTb as a carrier to enhance… Continue reading Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens